OTCMKTS:JBPHF Jacobio Pharmaceuticals Group (JBPHF) Stock Price, News & Analysis $0.87 0.00 (0.00%) As of 05/1/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Jacobio Pharmaceuticals Group Stock (OTCMKTS:JBPHF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get JBPHF alerts:Sign Up Key Stats Today's Range$0.87▼$0.8750-Day Range$0.83▼$0.8752-Week Range$0.73▼$1.10VolumeN/AAverage Volume308 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Jacobio Pharmaceuticals Group Co., Ltd. is a clinical‐stage biopharmaceutical company headquartered in Tianjin, China, specializing in the discovery and development of small‐molecule therapeutics for oncology. The company’s research platform is built around targeted kinase inhibitors and epigenetic modulators aimed at addressing acute leukemias and select solid tumors with high unmet medical need. Jacobio’s pipeline comprises multiple preclinical and clinical‐stage programs focused on genetically defined cancers, including agents designed to inhibit mutant FLT3, menin‐MLL interactions and other oncogenic drivers. Through its internal R&D capabilities, the company advances its lead candidates from target validation through Phase I/II studies, seeking to establish proof-of-concept in both monotherapy and combination regimens. Since its founding in 2007, Jacobio has expanded its footprint across mainland China, with research centers in Tianjin and collaborative networks involving academic institutions and contract research organizations. The company maintains in-house manufacturing capacity for early-stage compounds and pursues strategic partnerships to support late-stage development and potential global commercialization.AI Generated. May Contain Errors. Read More Receive JBPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jacobio Pharmaceuticals Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JBPHF Stock News HeadlinesJacobio Secures US$100 Million Upfront From AstraZeneca for Pan-KRAS Cancer DrugMarch 29, 2026 | tipranks.comJacobio Pharma: Differentiated Pan-KRAS Profile, Multiple Clinical Catalysts, and Solid Balance Sheet Underscore Buy RatingMarch 12, 2026 | tipranks.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 5 at 1:00 AM | Paradigm Press (Ad)Jacobio’s JAB-2485 Trial Progress: Early Cancer Data in Focus for HK:1167 InvestorsJanuary 9, 2026 | tipranks.comJacobio Strikes Up to US$1.9 Billion Global KRAS Inhibitor Deal With AstraZenecaDecember 21, 2025 | tipranks.comJacobio Pharmaceuticals Secures RMB125 Million to Advance Oncology PipelineDecember 1, 2025 | tipranks.comJacobio’s KRAS G12C and SHP2 Therapy Shows Promising Results in Clinical TrialsNovember 30, 2025 | tipranks.comJacobio Pharmaceuticals Unveils Promising Preclinical Data for Pan-KRAS InhibitorOctober 23, 2025 | tipranks.comSee More Headlines JBPHF Stock Analysis - Frequently Asked Questions How have JBPHF shares performed this year? Jacobio Pharmaceuticals Group's stock was trading at $0.9479 at the start of the year. Since then, JBPHF shares have decreased by 8.5% and is now trading at $0.8677. How do I buy shares of Jacobio Pharmaceuticals Group? Shares of JBPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:JBPHF CIKN/A Webwww.jacobiopharma.com Phone86-10-5631-5466FaxN/AEmployees301Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (OTCMKTS:JBPHF) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jacobio Pharmaceuticals Group Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jacobio Pharmaceuticals Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.